GERN News 1.94 Geron Corp (GERN)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Geron Corp (GERN) 1.94 $GERN

Prana Biotechnology Stock Hits New Low
ACCESSWIRE - Wed Apr 16, 9:47AM CDT
Prana Biotechnology (NASDAQ RAN) share value has been tumbling over the last month, closing at $1.74 Apr. 15, down 15 cents from the previous day's close of $1.89.

5 Unlikely Companies Bucking the Biotech Sell-Off
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 15, 11:05AM CDT
Over the past month biotech stocks have been absolutely bludgeoned, with the SPDR S&P Biotech ETF down 22.4%. I've offered my two cents on the subject previously and surmised the the dramatic fall is based on some combination of unrealistic...

Global Polycythemia Vera Therapeutic Pipeline Review 2014 - Analysis of 6 Companies and 7 Drug Profiles
M2 - Tue Apr 15, 6:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fn53p5/polycythemia_vera) has announced the addition of the "Polycythemia Vera - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Polycythemia Vera, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycythemia Vera and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Polycythemia Vera - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Polycythemia Vera and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Polycythemia Vera products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Polycythemia Vera pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Polycythemia Vera - Companies Involved in Therapeutics Development - Eli Lilly and Company - Incyte Corporation - Geron Corporation - Italfarmaco S.p.A. - PharmaEssentia Corporation - miRagen Therapeutics, Inc. Drug Profiles - ruxolitinib phosphate - peginterferon alfa-2b - imetelstat sodium - givinostat - gandotinib - MGN-4893 - Small Molecules to Inhibit JAK for Oncology and Hematological Disorders For more information visit http://www.researchandmarkets.com/research/fn...hemia_vera

Shorts Are Piling Into These Stocks. Should You Be Worried?
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 14, 12:45PM CDT
The best thing about the stock market is that you can make money in  either direction . Historically, stock indexes tend to trend upward over the long term. But when you look at individual stocks, you'll find plenty that lose money over the long...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Geron Corporation of Class Action Lawsuit and Upcoming Deadline -- GERN
GlobeNewswire - Fri Apr 11, 3:12PM CDT
Pomerantz LLP announces the filing of a class action lawsuit against Geron Corporation ("Geron" or the "Company" (Nasdaq:GERN) and certain of its officers. The class action, filed in United States District Court, Northern District of California and docketed under 14-cv-01424, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Geron between June 16, 2013 and March 11, 2014, both dates inclusive (the "Class Period" . This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Geron Corporation
Business Wire - Thu Apr 10, 9:32AM CDT
Law Offices of Howard G. Smith reminds investors that all purchasers of the securities of Geron Corporation ("Geron" or the "Company" (NASDAQ:GERN) between June 16, 2013 and March 11, 2014, inclusive (the "Class Period" , have until May 13, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.

Hagens Berman Reminds Investors of May 13, 2014, Lead Plaintiff Deadline in Geron Securities Class Action
Business Wire - Wed Apr 09, 12:38PM CDT
Hagens Berman Sobol Shapiro LLP a national investor-rights law firm, is investigating Geron Corporation (NASDAQ: GERN) ("Geron" or "the Company" for securities fraud following allegations that the company distributed false and misleading statements to investors concerning its business and prospects, and advises investors of the May 13, 2014 lead plaintiff deadline. Investors who have suffered significant financial losses, and who want to discuss their options, can contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by emailing Geron@hbsslaw.com or by calling 510-725-3000.

Top Gainers Technical Data -- Research on First Solar, Ctrip.com Intl., Geron, and Kandi Technologies
PR Newswire - Wed Apr 09, 7:23AM CDT
The US markets saw a positive sentiment on Tuesday, April 08, 2014, with the NASDAQ Composite closing at 4,112.99, up 0.81%, the Dow Jones Industrial Average ending the session at 16,256.14, up 0.06%, and the S&P 500 edging 0.38% higher to finish the trading session at 1,851.96. The session saw a positive impact from Consumer Discretionary, Energy and Utilities sectors along with a drag from Health Care, Industrials and Telecommunication Services sectors. A number of stocks saw large movements, including First Solar Inc. (NASDAQ: FSLR), Ctrip.com International Ltd (NASDAQ: CTRP), Geron Corp. (NASDAQ: GERN) and Kandi Technologies Group Inc. (NASDAQ: KNDI). Free technical research on FSLR, CTRP, GERN and KNDI can be downloaded upon signing up at:

Lieff Cabraser Announces Class Action Litigation Against Geron Corporation - GERN
Business Wire - Mon Apr 07, 3:28PM CDT
The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been brought on behalf of those who purchased or otherwise acquired the securities of Geron Corporation ("Geron" or the "Company" (NasdaqGS: GERN) between June 16, 2013 and March 11, 2014, inclusive (the "Class Period" .

Is Now the Time to Invest in Agios Pharmaceuticals, Inc?
George Budwell, The Motley Fool - Motley Fool - Mon Apr 07, 10:17AM CDT
Shares of Agios Pharmaceuticals spiked over 20% this morning after the company announced that its early stage blood cancer drug, AG-221, is showing unexpectedly strong efficacy signals. Specifically, six of the seven evaluable patients exhibited...

Geron Corporation (GERN) Analyst Report: High Potential High Risk Biopharmaceutical Firm Seeking to Advance Novel Innovative Cancer Treatment for myeloid malignancies by BrokerBank Securities, Inc.
PR Newswire - Mon Apr 07, 6:00AM CDT
Geron Corporation (NasdaqGS: GERN), an emerging competitor, is developing a telomerase inhibitor called Imetelstat in hematologic myeloid malignancies. Through internal efforts and potential future strategic partnerships, GERN is positioned to advance the commercialization of Imetelstat in one or more hematologic myeloid malignancies. The discovery and early development of Imetelstat was based on Geron's core expertise in telomerase and telomere biology. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides them with the capacity for limitless proliferation.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against GERON CORPORATION and Its Board of Directors and a Lead Plaintiff Deadline of May 13, 2014 -- GERN
GlobeNewswire - Fri Apr 04, 10:43AM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of investors who purchased Geron Corporation ("Geron" or the "Company" (Nasdaq:GERN) common stock between June 16, 2013 to March 11, 2014.

ALERT: Rosen Law Firm Reminds Geron Corporation Investors of Important Class Action Deadline -- GERN
GlobeNewswire - Thu Apr 03, 4:48PM CDT
The Rosen Law Firm, P.A. reminds all purchasers of the common stock of Geron Corporation (Nasdaq:GERN) from June 16, 2013 through March 11, 2014, of the important May 13, 2014 lead plaintiff deadline in the class action.

Are These 3 Biotechs Bad News Buys?
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 03, 8:30AM CDT
March wasn't kind to many of biotech's hottest names. From Geron to Exelixis , many of biotech's most talked-about stocks suffered headache-inducing falls over the past month. Biotech's had a good run lately with the market's rise, and while...

Geron to Present at the Needham Healthcare Conference
Thomson Reuters ONE - Wed Apr 02, 6:31AM CDT
MENLO PARK, Calif., April 2, 2014 - Geron Corporation (Nasdaq: GERN) today announced that John Scarlett, M.D., President and Chief Executive Officer, will present an overview of the company at the 13th Annual Needham Healthcare Conference in New York. The presentation is scheduled to occur at 8:00 a.m. Eastern Time on Tuesday, April 8th.

Hagens Berman Advises Investors of May 13, 2014, Deadline in Geron Corporation Securities Lawsuit and Investigation
Business Wire - Mon Mar 31, 2:52PM CDT
Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, is investigating Geron Corporation (NASDAQ: GERN) ("Geron" or "the Company" for securities fraud following allegations that the company distributed false and misleading statements to investors concerning its business and prospects, and advises investors of the class-action lead plaintiff deadline on May 13, 2014. Investors who have suffered significant financial losses, and who want to discuss their options, can contact a Hagens Berman attorney by emailing Geron@hbsslaw.com.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Geron Corporation and Certain Officers -- GERN
GlobeNewswire - Fri Mar 28, 12:11PM CDT
Pomerantz LLP announces the filing of a class action lawsuit against Geron Corporation ("Geron" or the "Company" (Nasdaq:GERN) and certain of its officers. The class action, filed in United States District Court, Northern District of California and docketed under 14-cv-01424, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Geron between June 16, 2013 and March 11, 2014, both dates inclusive (the "Class Period" . This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

Geron (GERN) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 7:09AM CDT
Geron (GERN) Enters Oversold Territory

Facility Investments, Earnings Release Schedules, Definitive Agreements, Patient Enrollments, and Clinical Trial Updates - Analyst Notes on Novo Nordisk, HealthSouth, AMRI, Abiomed, and Geron
PR Newswire - Thu Mar 27, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Novo Nordisk A/S (NYSE: NVO), HEALTHSOUTH Corp. (NYSE: HLS), Albany Molecular Research Inc. (NASDAQ: AMRI), Abiomed Inc. (NASDAQ: ABMD), and Geron Corporation (NASDAQ: GERN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Geron Corporation
PR Newswire - Wed Mar 26, 4:03PM CDT
Ryan & Maniskas, LLP announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of purchasers the securities of Geron Corporation ("Geron" or the "Company" (NASDAQ: GERN) between June 16, 2013 and March 11, 2014, inclusive (the "Class Period" .
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 211

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Armada Moves up as Key Player in US SI Exports

Updated Category News Views 163

Pioneering New Grounds in Intelligence Infrastructure Hell of a move by Armada, stepping into the limelight as a priority team leader in the U.S. SI Exports Program. The whole gig is under the Department of Commerce's belt, pushing the frontier of America's Super Intelligence (SI) technology to buddies across the globe. It's like watching the next big blockbuster unfold...

Continue Reading
Chicago Auto Show: Run & Explore Indoors This February

Updated Category News Views 188

Nobody’s thinking about running laps when they walk into a colossal auto show, but the Chicago Auto Show isn't letting the pedal ease off the gas. Swing by on February 14, folks, for something not typically seen on the floors of McCormick Place. Run participants have got one hour to log as many miles as they can on the 2.4-mile loop right inside the show. Why a Running...

Continue Reading
Operation Healing Forces Partners with Wounded Warrior

Updated Category News Views 68

Joining Forces for Special Operations Families When it comes to the heavy lifting of supporting Special Operations Forces (SOF) families, two powerhouses—Operation Healing Forces (OHF) and Wounded Warrior Project (WWP)—are doubling down. They’re not just tossing around good intentions. Oh no, they’re pulling out the stops with a solid partnership focused on...

Continue Reading
Kos & FORTH Partner to Spark Greek Biotech Growth

Updated Category News Views 81

New Frontiers: Greece on the Biotech Map Partnerships in biotech aren't tossed out willy-nilly; they're crafted for precision much like a sculptor shaping marble. Kos Biotechnology Partners and the Foundation for Research and Technology-Hellas (FORTH) are doing exactly that, teaming up to birth a biotechnology incubator on the FORTH campus in Heraklion, Crete. Now tell...

Continue Reading
Cardio Partners Hits a Million Milestone with Red Cross

Updated Category News Views 85

One Million Trained, One Million Prepared Ah, a million sounds like just another number, doesn't it? But when someone's life hangs in the balance, those are a million folks ready to jump in and act. Cardio Partners has hit this mighty milestone in CPR, AED, and First Aid training, gaining a pat on the back from none other than the American Red Cross. It's a testament,...

Continue Reading
Sandals Foundation: Win a Trip, Boost Caribbean Education

Updated Category News Views 226

Sandals Resorts Stakes a Claim in Education While the rest of us are gravitating towards Black Friday deals and Cyber Monday sales, the Sandals Foundation decided to play a different game. This Giving Tuesday, they invite travelers not just to soak in the sun, but to spread a little of it around by supporting education for kids across the Caribbean. It's a classic example...

Continue Reading
DHL Leverages Robust Growth in Resilient Supply Chains

Updated Category News Views 158

Supply Chain Resilience: A Strategic Game Changer Market volatility's got its teeth in the game, and everyone in logistics knows it. DHL Supply Chain isn't just sitting back; they're riding the wave of change, snagging a 12% revenue bump in 2026. It's not your typical headline growth, either. More like the kind of growth that gets logistics gurus eyeing those contract...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 237

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
PawnMate Boosts Inventory Efficiency for Pawnshops

Updated Category News Views 101

RFID Technology: Breathing New Life into Pawnshops Let's get things rolling with the cold, hard truth that pawnshops aren't exactly what most folks expect when it comes to cutting-edge technology. But times are a-changin', and PawnMate’s RFID Inventory Module is the latest twist in this industry storyline. It's like swapping out a rusty toolbox for a brand-new set of...

Continue Reading

Top 5 Most Recently Viewed Articles

Easterly ROCMuni Fund Investors: Understanding Your Rights

Updated Category News Views 110

Understanding the Easterly ROCMuni Fund Situation The Easterly ROCMuni High Income Municipal Bond Fund, formerly known as Principal Street High Income Municipal Fund, has recently come under scrutiny regarding its investment practices. Investors in the fund are encouraged to reach out to legal professionals to discuss potential claims related to significant financial...

Continue Reading
Is Bitcoin Ready for a Breakout Amid Bullish Sentiment?

Updated Category News Views 111

Bitcoin's Current Market Position Bitcoin (BTC/USD) is currently positioned near $115,000, just a day before significant decisions regarding interest rates by the Federal Reserve. Expectations are high, as many anticipate a rate cut of 25 basis points, which is igniting market discussions and predictions. Current Market Sentiment Recent data from Santiment highlights an...

Continue Reading
Nyxoah's Upcoming Presentation at Healthcare Conference Revealed

Updated Category News Views 168

Nyxoah to Present at Healthcare Conference Nyxoah SA, a leader in medical technology focused on treating Obstructive Sleep Apnea (OSA), is poised to showcase its advancements at an upcoming prominent event. The company will take part in the Piper Sandler 36th Annual Healthcare Conference, scheduled for December 4. This notable event is set to provide a platform for Nyxoah...

Continue Reading
Keros Therapeutics Welcomes Dr. Yung H. Chyung as CMO

Updated Category News Views 176

Keros Therapeutics Welcomes New Leadership Keros Therapeutics, Inc. (NASDAQ: KROS) is making waves with the recent appointment of Dr. Yung H. Chyung as their new Chief Medical Officer. This pivotal move signals the company's commitment to advancing its innovative drug development efforts, especially as they gear up for critical clinical milestones. Keros is known for its...

Continue Reading
Nestlé's Strategic Shake-Up: Leadership Changes and Impacts

Updated Category News Views 303

Unexpected Leadership Change at Nestlé In a surprising turn of events, Nestlé has dismissed its Chief Executive Officer, Laurent Freixe, due to his failure to communicate a romantic relationship with an employee who worked under his supervision. This decision highlights the strict adherence to corporate governance rules that Nestlé aims to uphold. Philipp Navratil...

Continue Reading